Amgen, Inc. (AMGN) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its stake in Amgen, Inc. (NASDAQ:AMGN) by 6.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,778,645 shares of the medical research company’s stock after selling 117,696 shares during the period. Amgen makes up 0.4% of Renaissance Technologies LLC’s holdings, making the stock its 21st largest position. Renaissance Technologies LLC’s holdings in Amgen were worth $260,056,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of AMGN. Third Avenue Management LLC boosted its stake in Amgen by 56.6% in the fourth quarter. Third Avenue Management LLC now owns 210,262 shares of the medical research company’s stock worth $30,742,000 after buying an additional 76,036 shares during the last quarter. Stratos Wealth Partners LTD. raised its position in Amgen by 10.6% in the third quarter. Stratos Wealth Partners LTD. now owns 39,257 shares of the medical research company’s stock worth $6,548,000 after buying an additional 3,776 shares during the period. 1st Global Advisors Inc. raised its position in Amgen by 21.5% in the third quarter. 1st Global Advisors Inc. now owns 10,592 shares of the medical research company’s stock worth $1,767,000 after buying an additional 1,871 shares during the period. BancorpSouth Inc raised its position in Amgen by 2.3% in the third quarter. BancorpSouth Inc now owns 24,838 shares of the medical research company’s stock worth $4,143,000 after buying an additional 552 shares during the period. Finally, WASHINGTON TRUST Co raised its position in Amgen by 0.3% in the third quarter. WASHINGTON TRUST Co now owns 52,132 shares of the medical research company’s stock worth $8,695,000 after buying an additional 139 shares during the period. Institutional investors own 79.04% of the company’s stock.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at 168.61 on Monday. The company’s 50-day moving average is $171.88 and its 200-day moving average is $159.85. The company has a market capitalization of $124.17 billion, a price-to-earnings ratio of 16.47 and a beta of 1.15. Amgen, Inc. has a 12-month low of $133.64 and a 12-month high of $184.21.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, February 2nd. The medical research company reported $2.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.10. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The business earned $5.97 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same period last year, the firm posted $2.61 EPS. The company’s revenue was up 7.7% on a year-over-year basis. Analysts predict that Amgen, Inc. will post $12.31 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Wednesday, May 17th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date of this dividend is Monday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 44.92%.

Your IP Address:

AMGN has been the topic of a number of recent research reports. Royal Bank of Canada set a $190.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Wednesday, January 4th. Zacks Investment Research lowered shares of Amgen from a “hold” rating to a “sell” rating in a research report on Tuesday, January 3rd. Leerink Swann set a $163.00 price target on shares of Amgen and gave the company a “hold” rating in a research report on Monday, November 21st. Bank of America Corp raised shares of Amgen from a “neutral” rating to a “buy” rating and raised their price target for the company from $156.68 to $192.00 in a research report on Wednesday, February 1st. Finally, Credit Suisse Group AG lowered shares of Amgen from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $200.00 to $180.00 in a research report on Tuesday, December 20th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $187.41.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/amgen-inc-amgn-shares-sold-by-renaissance-technologies-llc/1708642.html

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *